Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Aurinia Pharmaceuticals ( ($AUPH) ) has released its Q3 earnings. Here is a breakdown of the information Aurinia Pharmaceuticals presented to its ...

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...